Why Amylyx Pharmaceuticals Stock Was So Healthy This Week

The past few days have been very pleasant for biotech company Amylyx Pharmaceuticals (NASDAQ: AMLX). As is often the case with companies in that sector, Amylyx's stock has recently seen a dramatic rise thanks to news from the laboratory. The company's stock was rising by a bit over 10% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.Amylyx's encouraging news concerned its pipeline drug AMX0035, which targets the rare genetic disorder Wolfram Syndrome. The company reported that a phase 2 clinical trial conducted on 12 adults with the affliction met its primary efficacy endpoint. This was to demonstrate improvement in the function of the pancreas; Wolfram typically degrades this over time, in addition to affecting other organs in the body. The biotech added that longer-term data indicate "sustained improvement," while being administered the drug. Overall, the treatment was well tolerated by the patients during the study. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool